EDITION:

Search
Search
Close this search box.

Apollon Formularies to serve South Africa with new venture

Home » Apollon Formularies to serve South Africa with new venture

UK-based Apollon Formularies is entering into a joint venture in South Africa with Tri-Medi Canna to establish the jointly owned Apollon SA Pty Ltd.

The establishment of the jointly owned company with Tri-Medi Canna, based in South Africa, is Apollon Formularies’ first international expansion.

With the aim of establishing a strong foothold in the region, the company has said it will be working to make its medical cannabis formulations available for a number of cancer conditions to more patients whilst continuing to collect data. The company has previously stated that its formulations have shown to be effective at fighting prostate cancer and at killing HER2+ breast cancer cells.

Read more: Apollon Formularies opens new cannabis cancer and pain clinic in Jamaica

Stene Jacobs, COO of Apollon Formularies for Europe and Africa, commented: “This is a major step forward in Apollon’s plans to reach global markets and the African market which still remains largely untapped. 

“Tri-Medi Canna’s relationship with necessary key stakeholder in South Africa will provide Apollon with the platform to infiltrate this market, whilst providing the local community with access to training, knowledge and skills and contribute to local employment.

“South Africa has the opportunity to build on its reputation as the regional best in class operator and to showcase its already successful cultivation and plant genetics abilities. In conjunction with this, the South African medical fraternity is deeply admired for being at the forefront of medical advancements, with deep scientific knowledge in conventional and alternate medicine.

“This joint venture agreement validates Apollon’s business model in Jamaica and our ability to replicate and scale up operations to other international jurisdictions. We look forward to keeping the market updated on our progress as we enter this exciting chapter in Apollon’s journey.”

Apollon recently made the announcement it has opened its new International Cancer and Chronic Pain Institute (ICCPI) in Kingston, Jamaica, which will specialise in complementary and alternative medical treatments for cancer patients, prescribing Apollon’s own products. 

As part of the South African joint venture, Tri-Medi Canna will will apply for licenses to replicate those held by Apollon in Jamaica and will provide Apollon access to the South African market as well as the wider SADC region.

Read more: Apollon Formularies intends to advance to a larger exchange

Tri-Medi Canna will also gain access to Apollon’s vast experience across the value chain and the exclusive licensed distribution of Apollon’s proprietary products and formulations once the necessary licenses have been granted by SAHPRA, allowing Tri-Medi Canna to benefit from Apollon’s ongoing international exposure to European markets.

CEO of Tri-Medi Canna, Thokozani Shongwe, stated: “We are delighted to be working with Apollon Formularies as we expand our offering across South Africa and grow our knowledge and skill base through this partnership. 

“Apollon has forged firm routes in Jamaica and its proprietary formulas have consistently proven to be effective during rigourous testing on pre-clinical third-party pharmaceutical laboratory testing conduced in the US on 3D Cell cultures.

“This is a crucial time in the development of the African cannabis sector, and I am proud that Tri-Medi Canna can work with Apollon to establish a strong foothold from which to expand into the SADC and beyond.”

Tri-Medi Canna will work to obtain letters of support from South African Government’s Department of Trade and Industry, Agricultural Research Council and clinical specialists working collaboratively on cannabis research at the University of Kwazulu Natal to support continuing research and development in the medical cannabis sector.

[activecampaign form=31]

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?